Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sexual supplement recall

This article was originally published in The Tan Sheet

Executive Summary

In its latest warning on adulterated supplements sold as treatments for erectile dysfunction, FDA advises consumers not to use Blue Steel or Hero products distributed by Active Nutraceuticals because they are considered unapproved drugs and have not been proven to be safe or effective. The products contain undeclared and unapproved substances similar in chemical structure to sildenafil (Pfizer's Viagra), FDA says. "Because these products are labeled as 'all natural dietary supplements,' consumers may assume that they are harmless and pose no health risk," but the sildenafil may interact with nitrates found in some prescription drugs and can lower blood pressure to dangerous levels, the agency says (1"The Tan Sheet" Jan. 28, 2008, p. 11). Active, a unit of Carrollton, Ga.-based Marion Group, distributes Blue Steel in 10-count bottles or in blister packs and Hero in two-capsule blister packs...

You may also be interested in...

FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Medaxes Sets Out Hopes For Belgian Biosimilars Taskforce

Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts